Skip to main content

Table 2 Clinical characteristics of the populations with liver tissues enrolled in the study

From: IFI16 is involved in HBV-associated acute-on-chronic liver failure inflammation

group NC CHB HBV-ACLF
case 19 59 17
sex(M/F) ND 46/13 16/1
age(years) ND 37(23-65) 41(29-61)
ALT(U/L) ND 50(7-570) 40(11-156)
AST(U/L) ND 37(15-256) 92(40-202)
Tbil(umol/L) ND 12.1(2.6-119.9) 600.6(238-809)
INR ND 1.03(0.87-1.35) 2.88(2.11-5.83)
PTA(%) ND 95(63-128) 21(11-35)
Log10 (HBV DNA) ND 5.42(0-8.54) 2(0.83-8.05)
HBsAg-positive ND 59 17
HBsAb-positive ND 0 0
HBeAg-positive ND 24 2
HBeAb-positive ND 35 15
HBcA-bpositive ND 59 17
MELD score ND ND 33.33±2.02
  1. Data are shown as median and range
  2. ACLF, acute on chronic liver failure; CHB, chronic hepatitis B; ALT, alanine aminotransferase;AST, aspartate aminotransferase; Tbil, total bilirubin; HBcAb, hepatitis B c antibody; HBeAb, hepatitis B e antibody;HBeAg, hepatitis B e antigen; HBsAb, hepatitis B s antibody; HBsAg, hepatitis B s antigen; HBV, hepatitis B virus; ND, not determined; NC, normal control; PTA, prothrombin time activity. MELD Model for end-stage liver disease.